Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Amneal Pharmaceuticals receives FDA approval for Spironolactone HCl tablets

Amneal Pharmaceuticals, LLC is pleased to announce that it has received U.S. FDA approval to manufacture Spironolactone HCl tablets in 25 mg, 50 mg and 100 mg strengths effective July 2, 2010.

26 Aug 2010

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

Medtronic, Inc. today announced it received Health Canada approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a novel radiofrequency ablation technology for the treatment of atrial fibrillation. AF is the most common heart arrhythmia that affects more than 250,000 Canadians and seven million people worldwide.

26 Aug 2010

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutic agents for the treatment of cardiovascular disease, today announced that it has initiated a dose-defining Phase IIa trial of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure.

26 Aug 2010

Angeion Corporation 2010 third quarter revenue increases to $7.1 million

Angeion Corporation today reported results for its fiscal third quarter ended July 31, 2010.

26 Aug 2010

HCM patients undergoing transplant can expect reasonable long-term survival rates: Research

Transplant surgery to correct the most common type of genetic heart disease yields similar short-term and potentially greater long-term survival rates as transplant surgery for other heart diseases, according to research reported in Circulation: Heart Failure, an American Heart Association journal.

25 Aug 2010

Reducing patient body temperature with cold salt beneficial for patients undergoing balloon angioplasty

Treating heart attack patients with hypothermia reduces the amount of heart damage by more than one third after balloon angioplasty. Researchers in Lund, Sweden have today released the results of a study showing that the amount of heart damage in heart attack patients whose body temperature was lower than 35˚C (95˚F) was reduced by more than one third after they were treated with balloon angioplasty to open their clogged heart vessel.

25 Aug 2010

Two diabetes medications increase risk of heart attack, failure: Study

In contrast to previous reports, the risks of the composite endpoint of heart attack, heart failure, both, or death were the same about 4 percent for patients taking the diabetes drugs rosiglitazone or pioglitazone, according to a study published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

25 Aug 2010

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer Inc. announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC).

24 Aug 2010

Cedars-Sinai opens Advanced Heart Failure Unit in California

The Cedars-Sinai Heart Institute has opened an innovative 30-bed in-patient unit dedicated to providing advanced heart failure patients with an intensive, multidisciplinary approach to inpatient care.

20 Aug 2010

Cancer patients may live longer with palliative and hospice care services: Study

A new study released by the New England Journal of Medicine found that among patients with non-small-cell lung cancer, those who received palliative care lived, on average, almost two months longer than those who received standard care. Researchers also found that the patients receiving palliative care reported a higher quality of life through the final course of their illness.

20 Aug 2010

St. Vincent's Hospital performs Australia's first implant of SynCardia temporary Total Artificial Heart

On Aug. 5, St. Vincent's Hospital in Sydney performed Australia's first implant of the SynCardia temporary Total Artificial Heart. The patient, a 50-year-old male suffering from total heart failure, is the first recipient of the Total Artificial Heart in the Southern Hemisphere. The surgery was performed by heart surgeons Drs. Phillip Spratt and Paul Jansz.

20 Aug 2010

Results from TITAN trial of CARILLON Mitral Contour System to be presented at ESC 2010 Congress

Cardiac Dimensions, an early stage company focused on the development of minimally invasive devices for the treatment of mitral valve disease and congestive heart failure, announced today that the 12-month follow-up results from the TITAN trial of the Company's CARILLON Mitral Contour System will be presented at the European Society of Cardiology 2010 Congress on August 29, 2010 in Stockholm.

18 Aug 2010

Dysphagia impacts length of hospital stay and prognosis

Researchers from Mount Sinai School of Medicine have found that hospitalized patients with dysphagia, or difficulty swallowing, averaged a 40 percent longer hospital stay than patients without the condition. They also had a generally poorer prognosis. The research is published in the August issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.

18 Aug 2010

Moderate chocolate consumption lowers heart failure risk: Study

Middle-aged and elderly Swedish women who regularly ate a small amount of chocolate had lower risks of heart failure risks, in a study reported in Circulation: Heart Failure, a journal of the American Heart Association.

18 Aug 2010

PRA International to host audio conference on CV drug development strategy

PRA International, a leading Clinical Research Organization, will host an audio conference on strategies for successful cardiovascular (CV) drug development on 24 August 2010 at 11:30 am (EDT). Dr. Michael Kirchengast, Vice President and Head of PRA's Scientific Affairs unit, will be the presenter.

17 Aug 2010

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication.

17 Aug 2010

Human adult stem cells can regenerate damaged heart tissue: Research

Mayo Clinic investigators, with Belgian collaborators, have demonstrated that rationally "guided" human adult stem cells can effectively heal, repair and regenerate damaged heart tissue. The findings called "landmark work" in an accompanying editorial appear in today's Journal of the American College of Cardiology.

17 Aug 2010

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

17 Aug 2010

Australia’s first artificial heart in place

Angelo Tigano, 50 was given only two weeks to live at the start of this month. But last week surgeons at St Vincent's Hospital, Sydney gave him the country's first artificial heart after a five-hour operation to keep him alive.

16 Aug 2010

Massachusetts General Hospital implants Levacor Ventricular Assist Device

World Heart Corporation, a developer of mechanical circulatory systems, announced today that the Massachusetts General Hospital in Boston, Mass. has successfully implanted its first Levacor™ Ventricular Assist Device (VAD). Mass General is the fifth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the eleventh implant with the Levacor VAD since the inception of the BTT study.

16 Aug 2010

Heart Failure News and Research

Further Reading

Amneal Pharmaceuticals receives FDA approval for Spironolactone HCl tablets

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

Angeion Corporation 2010 third quarter revenue increases to $7.1 million

HCM patients undergoing transplant can expect reasonable long-term survival rates: Research

Reducing patient body temperature with cold salt beneficial for patients undergoing balloon angioplasty

Two diabetes medications increase risk of heart attack, failure: Study

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Cedars-Sinai opens Advanced Heart Failure Unit in California

Cancer patients may live longer with palliative and hospice care services: Study

St. Vincent's Hospital performs Australia's first implant of SynCardia temporary Total Artificial Heart

Results from TITAN trial of CARILLON Mitral Contour System to be presented at ESC 2010 Congress

Dysphagia impacts length of hospital stay and prognosis

Moderate chocolate consumption lowers heart failure risk: Study

PRA International to host audio conference on CV drug development strategy

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Human adult stem cells can regenerate damaged heart tissue: Research

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Australia’s first artificial heart in place

Massachusetts General Hospital implants Levacor Ventricular Assist Device

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News